日本与我国台湾地区药品不良反应损害救济基金制度的比较及对我国的启示
x

请在关注微信后,向客服人员索取文件

篇名: 日本与我国台湾地区药品不良反应损害救济基金制度的比较及对我国的启示
TITLE:
摘要: 目的:为构建我国药品不良反应损害(简称“药害”)救济基金制度提供参考。方法:借鉴日本和我国台湾地区的药害救济制度,从基金设立的法律依据、主管机构性质、筹资来源、筹资比例和救济力度等方面进行对比研究,并对我国药害救济基金制度的构建提出建议。结果与结论:日本与我国台湾地区的药害救济基金均依法建立,但因行政管理制度、筹资来源、筹资比例和救济力度均有不同,在筹资模式各要素中呈现出某些共性(如均设立了相关法律、主管机构与其卫生部门的合作关系)与特异点(如基金主管机构性质,日本为独立行政法人、我国台湾地区为独立财团法人等)。我国建立药害救济基金制度时应加快推进相关立法,政府应合理安排基金管理机构,分阶段循序渐进建立药害救济基金,增强公众对药害救济基金的认知,建立以企业缴费为主的多元化筹资途径。
ABSTRACT: OBJECTIVE: To provide reference for constructing relief fund system for adverse drug reactions (ADR) in China. METHODS: Referring to the ADR damage relief system in Japan and Taiwan area of China, comparative study was conducted from aspects of the legal basis of the fund establishment, the nature of the authority, financing sources and ratio, relief efforts, etc. And rationalization suggestions were put forward for constructing the relief fund system for ADR in China. RESULTS & CONCLUSIONS: The ADR damage relief fund system of Japan and Taiwan area of China was established by the law. However, due to different administrative system, financing sources and ratio, and relief efforts, there were some similarities (setting related laws, showing similarities in the partnerships between authorities and its health departments) and differences (the nature of fund authorities were independent administrative body in Japan, independent corporation in Taiwan area of China and so on) in the elements of the financing model. When constructing the ADR relief fund system, China should accelerate the relevant legislation; the government should reasonably arrange fund management agency, gradually establish ADR damage relief fund step by step, enhance the public awareness of ADR damage relief fund and establish diversified financing modes with enterprise-based payment.
期刊: 2017年第28卷第22期
作者: 张枫,徐晓媛
AUTHORS: ZHANG Feng,XU Xiaoyuan
关键字: 药品不良反应;药品不良反应损害救济制度;日本;我国台湾地区
KEYWORDS: Adverse drug reaction; Adverse drug reaction damage relief system; Japan; Taiwan area of China
阅读数: 648 次
本月下载数: 16 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!